Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 4Active not recruiting 2

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6Genitourinary 1

Conditions

Stomach Neoplasms 6Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Adenocarcinoma 2Triple Negative Breast Neoplasms 1Squamous-Cell Non-Small-Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Gastrointestinal Neoplasms 1GastroEsophageal Cancer 1Gastric or Gastroesophageal Cancer 1Esophageal Neoplasms 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Adenocarcinoma of Lung 1

Interventions

Oxaliplatin 295Capecitabine 209Fluorouracil 183Cisplatin 172Docetaxel 140S 1 (combination) 135Paclitaxel 128Leucovorin 117Irinotecan 110pembrolizumab 104Trastuzumab 75Nivolumab 59apatinib 57Drug Therapy 52sintilimab 46Surgical Procedures, Operative 45Ramucirumab 40Radiotherapy 40Bevacizumab 37Hyperthermic Intraperitoneal Chemotherapy 34Epirubicin 32titanium silicide 31tislelizumab 31Carboplatin 31Gastrectomy 28Cyclophosphamide 27XELOX 25Tegafur 24Folfox protocol 23Albumin-Bound Paclitaxel 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Stomach Neoplasms × bemarituzumab × Clear all
NCT05052801 2026-05-27

FORTITUDE-101

Amgen

Phase 3 Completed
547 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05111626 2025-12-15

FORTITUDE-102

Amgen

Phase 3 Active not recruiting
515 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05322577 2025-12-05

FORTITUDE-103

Amgen

Phase 1/2 Active not recruiting
72 enrolled
Gastrointestinal

Stomach Neoplasms

NCT02318329 2024-06-04

Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors

Five Prime Therapeutics, Inc.

Phase 1 Completed
79 enrolled 21 charts
GastrointestinalGenitourinary

Urinary Bladder Neoplasms, Esophageal Neoplasms, Stomach Neoplasms

NCT03343301 2024-02-28

FIGHT

Five Prime Therapeutics, Inc.

Phase 1 Completed
12 enrolled 17 charts
Gastrointestinal

Gastrointestinal Neoplasms, Stomach Neoplasms

NCT03694522 2024-02-28

FIGHT

Five Prime Therapeutics, Inc.

Phase 2 Completed
155 enrolled 19 charts
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡